“Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single Center, Double-blind, Placebo Controlled, Phase 3 Trial ”, Acta Med Philipp, vol. 58, no. 6, Apr. 2024, doi: 10.47895/amp.vi0.6175.